Nkarta, Inc.
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (NCT06733935) | Nkarta, Inc. | 2024-11-04 |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) (NCT06557265) | Nkarta, Inc. | 2024-06-13 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678) | Nkarta, Inc. | 2021-08-20 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (NCT04623944) | Nkarta, Inc. | 2020-09-21 |
Track Nkarta, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.